Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889093 · ClinicalTrials.gov registry record · NA
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
A NA study, sponsored by University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03889093 is a NA study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 14 participants.
The verdict
NCT03889093, a NA study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.
Interventions
- OTHER Yttrium-90
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2022-02-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03889093
The ClinicalTrials.gov registry entry for NCT03889093 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Yttrium-90 is the first listed.
NCT03889093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03889093 about?
NCT03889093 is a clinical study titled "Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System". The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.
What is the current status of trial NCT03889093?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2018-08-09. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03889093?
The interventions under investigation include: Yttrium-90 (OTHER).
Who is sponsoring clinical trial NCT03889093?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.